Join INmune Bio for a virtual KOL event featuring Prof. Judith Jaeger, PhD, MPA and Sarah Barnum, PhD, ABPP from CognitionMetrics who will join CJ Barnum, PhD, VP of CNS Drug Development, to discuss the unmet need and current treatment landscape for patients with Early Alzheimer’s Disease (AD) with biomarkers of elevated neuroinflammation.

The event will focus on INmune Bio’s Phase 2 trial (AD02) in patients with Early AD and the importance of the trial’s primary endpoint, Early Mild Alzheimer’s Cognitive Composite (EMACC), as a validated cognitive measure in AD clinical trials. It will also highlight neuroinflammation as a target in AD treatment.

A live question and answer session will follow the formal presentation.